While the precise molecular cascade (e.g., whether HMGB1 promotes DDX3 degradation via ubiquitination) requires further investigation, our current data support a model in which HMGB1-driven DDX3 suppression releases MAPK pathway inhibition, thereby driving tumor progression. The gene discussed is HMGB1; the disease is neoplasm.